Carter Gould
Stock Analyst at Cantor Fitzgerald
(4.09)
# 1,637
Out of 4,600 analysts
637
Total ratings
52.1%
Success rate
6%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $590 → $595 | $476.89 | +24.77% | 11 | Aug 4, 2026 | |
| ABBV AbbVie | Maintained: Buy | $265 → $285 | $244.18 | +16.72% | 50 | Jul 31, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $54 → $59 | $64.25 | -8.17% | 36 | Jul 30, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintained: Buy | $750 → $795 | $755.78 | +5.19% | 53 | Jul 30, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $155 | $130.81 | +18.49% | 49 | Jul 28, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,230 → $1,350 | $1,124.00 | +20.11% | 100 | Jul 6, 2026 | |
| PFE Pfizer | Maintained: Hold | $27 | $25.35 | +6.53% | 60 | Jun 22, 2026 | |
| AMGN Amgen | Maintained: Hold | $350 | $383.23 | -8.67% | 48 | Apr 30, 2026 | |
| MRK Merck & Co. | Maintained: Hold | $120 | $127.66 | -6.00% | 44 | Mar 29, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | n/a | $77.28 | - | 18 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $54.09 | n/a | 2 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $204.20 | n/a | 45 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $54.93 | n/a | 24 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.1751 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $22.15 | n/a | 14 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $1.36 | n/a | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.55 | n/a | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $167.47 | n/a | 29 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.582951 | n/a | 9 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $160 | $235.02 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $98.88 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | €80.78 | €145.50 | n/a | 1 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $82 → $86 | $118.68 | n/a | 4 | Jul 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $94 | $516.64 | n/a | 1 | May 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $4 | $2.25 | n/a | 2 | Feb 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $2.8 | $8.17 | n/a | 2 | Jan 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $13 | $0.8724 | n/a | 2 | Nov 12, 2018 |
Vertex Pharmaceuticals
Aug 4, 2026
Maintained: Buy
Price Target: $590 → $595
Current: $476.89
Upside: +24.77%
AbbVie
Jul 31, 2026
Maintained: Buy
Price Target: $265 → $285
Current: $244.18
Upside: +16.72%
Bristol-Myers Squibb Company
Jul 30, 2026
Maintained: Hold
Price Target: $54 → $59
Current: $64.25
Upside: -8.17%
Regeneron Pharmaceuticals
Jul 30, 2026
Maintained: Buy
Price Target: $750 → $795
Current: $755.78
Upside: +5.19%
Gilead Sciences
Jul 28, 2026
Reiterated: Buy
Price Target: $155
Current: $130.81
Upside: +18.49%
Eli Lilly and Company
Jul 6, 2026
Maintained: Buy
Price Target: $1,230 → $1,350
Current: $1,124.00
Upside: +20.11%
Pfizer
Jun 22, 2026
Maintained: Hold
Price Target: $27
Current: $25.35
Upside: +6.53%
Amgen
Apr 30, 2026
Maintained: Hold
Price Target: $350
Current: $383.23
Upside: -8.67%
Merck & Co.
Mar 29, 2026
Maintained: Hold
Price Target: $120
Current: $127.66
Upside: -6.00%
Cytokinetics
Feb 25, 2026
Maintained: Buy
Price Target: n/a
Current: $77.28
Upside: -
Jun 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $54.09
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $204.20
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $54.93
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $0.1751
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $22.15
Upside: n/a
Nov 8, 2024
Rated: Buy
Price Target: $9
Current: $1.36
Upside: n/a
Nov 7, 2024
Maintained: Buy
Price Target: $12
Current: $1.55
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $160
Current: $167.47
Upside: n/a
Aug 14, 2024
Maintained: Buy
Price Target: $3
Current: $0.582951
Upside: n/a
Jan 11, 2023
Rated: Hold
Price Target: $160
Current: $235.02
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $98.88
Upside: n/a
Feb 27, 2020
Initiated Coverage: Buy
Price Target: €80.78
Current: €145.50
Upside: n/a
Jul 31, 2019
Maintained: Hold
Price Target: $82 → $86
Current: $118.68
Upside: n/a
May 17, 2019
Upgraded: Hold
Price Target: $94
Current: $516.64
Upside: n/a
Feb 1, 2019
Downgraded: Hold
Price Target: $16 → $4
Current: $2.25
Upside: n/a
Jan 11, 2019
Maintained: Hold
Price Target: $6 → $2.8
Current: $8.17
Upside: n/a
Nov 12, 2018
Maintained: Buy
Price Target: $18 → $13
Current: $0.8724
Upside: n/a